KR20220062372A - 약물 전달 제형 - Google Patents

약물 전달 제형 Download PDF

Info

Publication number
KR20220062372A
KR20220062372A KR1020227012200A KR20227012200A KR20220062372A KR 20220062372 A KR20220062372 A KR 20220062372A KR 1020227012200 A KR1020227012200 A KR 1020227012200A KR 20227012200 A KR20227012200 A KR 20227012200A KR 20220062372 A KR20220062372 A KR 20220062372A
Authority
KR
South Korea
Prior art keywords
risperidone
formulation
administration
poly
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012200A
Other languages
English (en)
Korean (ko)
Inventor
앙또니 헤슈
크리스토프 로베르쥬
에란 하라리
Original Assignee
메딘셀 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메딘셀 에스.에이. filed Critical 메딘셀 에스.에이.
Publication of KR20220062372A publication Critical patent/KR20220062372A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
KR1020227012200A 2019-09-13 2020-09-11 약물 전달 제형 Pending KR20220062372A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900061P 2019-09-13 2019-09-13
US62/900,061 2019-09-13
PCT/IB2020/058474 WO2021048817A1 (en) 2019-09-13 2020-09-11 Drug delivery formulations

Publications (1)

Publication Number Publication Date
KR20220062372A true KR20220062372A (ko) 2022-05-16

Family

ID=72521677

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012200A Pending KR20220062372A (ko) 2019-09-13 2020-09-11 약물 전달 제형

Country Status (19)

Country Link
US (3) US12383493B2 (cg-RX-API-DMAC7.html)
EP (2) EP4706658A3 (cg-RX-API-DMAC7.html)
JP (2) JP7661312B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062372A (cg-RX-API-DMAC7.html)
CN (1) CN114727946A (cg-RX-API-DMAC7.html)
AU (2) AU2020346455B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004535A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153793A1 (cg-RX-API-DMAC7.html)
DK (1) DK4027973T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058225T3 (cg-RX-API-DMAC7.html)
FI (1) FI4027973T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251690T1 (cg-RX-API-DMAC7.html)
IL (1) IL291283A (cg-RX-API-DMAC7.html)
LT (1) LT4027973T (cg-RX-API-DMAC7.html)
MX (1) MX2022003051A (cg-RX-API-DMAC7.html)
PL (1) PL4027973T3 (cg-RX-API-DMAC7.html)
PT (1) PT4027973T (cg-RX-API-DMAC7.html)
SI (1) SI4027973T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048817A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil
US20240148641A1 (en) * 2021-03-17 2024-05-09 Medincell S.A. Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007343A1 (en) * 1997-08-08 1999-02-18 University Of Utah Research Foundation Injectable biodegradable block copolymer gels for use in drug delivery
JP4223961B2 (ja) 2002-01-31 2009-02-12 Agcテクノグラス株式会社 霊長類胚性幹細胞の凍結保存方法
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
KR101707791B1 (ko) 2008-09-30 2017-02-17 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 리스페리돈 전달용 이식형 장치
CN101584652B (zh) * 2009-06-19 2012-06-20 上海医药集团股份有限公司 利培酮缓释凝胶注射剂及其制备方法
MY165655A (en) * 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
WO2013063125A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
KR102189442B1 (ko) * 2012-06-27 2020-12-11 메딘셀 에스.에이. 소수성 조성물용 생분해성 약물 전달
WO2014164754A1 (en) * 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
LT3655038T (lt) * 2017-07-17 2025-02-10 Medincell S.A. Farmacinė kompozicija
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil

Also Published As

Publication number Publication date
CA3153793A1 (en) 2021-03-18
AU2020346455A1 (en) 2022-03-31
JP2022548616A (ja) 2022-11-21
US20220331240A1 (en) 2022-10-20
JP7661312B2 (ja) 2025-04-14
BR112022004535A2 (pt) 2022-06-07
MX2022003051A (es) 2022-06-14
HRP20251690T1 (hr) 2026-02-13
US12128132B2 (en) 2024-10-29
IL291283A (en) 2022-05-01
ES3058225T3 (en) 2026-03-09
US12383493B2 (en) 2025-08-12
EP4706658A2 (en) 2026-03-11
CN114727946A (zh) 2022-07-08
US20250268817A1 (en) 2025-08-28
DK4027973T3 (da) 2026-01-12
PT4027973T (pt) 2026-01-05
AU2020346455B2 (en) 2025-07-03
FI4027973T3 (fi) 2026-01-14
PL4027973T3 (pl) 2026-03-09
SI4027973T1 (sl) 2026-02-27
LT4027973T (lt) 2026-01-26
WO2021048817A1 (en) 2021-03-18
EP4706658A3 (en) 2026-06-03
EP4027973B1 (en) 2025-11-05
US20240156722A1 (en) 2024-05-16
EP4027973A1 (en) 2022-07-20
JP2025106353A (ja) 2025-07-15
AU2025242078A1 (en) 2025-10-23
EP4027973B8 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
US12128132B2 (en) Drug delivery formulations
US20220354956A1 (en) Biodegradable drug delivery for hydrophobic compositions
AU2011350898B2 (en) Biodegradable drug delivery compositions
EP4574906A2 (en) Pharmaceutical composition
KR20080030024A (ko) 도세탁셀의 약제학적 액상제제
JP6356873B2 (ja) タキサン系活性成分含有液体組成物及び液体製剤
JP2007515425A (ja) 医薬組成物
AU2011273064B2 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
JP2009509942A (ja) フルベストラント製剤
AU2011273064A1 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
KR20200085809A (ko) 풀베스트란트 제제 및 그의 사용 방법
BR122025009310A2 (pt) Formulações de entrega de fármaco
US12329851B2 (en) Long acting injectable formulation comprising risperidone and biodegradable polymers
CN116997323A (zh) 包含利培酮和可生物降解的聚合物的长效可注射制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000